We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) (VCU-ART3)

This study is currently recruiting participants.
Verified August 2017 by Virginia Commonwealth University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01950299
First Posted: September 25, 2013
Last Update Posted: August 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Virginia Commonwealth University
  Purpose
VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.

Condition Intervention Phase
Acute Myocardial Infarction Drug: Anakinra 100 mg Drug: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3

Resource links provided by NLM:


Further study details as provided by Virginia Commonwealth University:

Primary Outcome Measures:
  • Acute phase response (CRP levels) [ Time Frame: 14 days ]
    Placebo corrected difference in the area-under-the-curve for CRP up to day 14


Secondary Outcome Measures:
  • Left ventricular end-systolic volume indices change [ Time Frame: 12 months ]
    Placebo corrected interval change in left ventricular end-systolic volume indices over 12 months

  • Left ventricular ejection fraction [ Time Frame: 12 months ]
    Placebo-corrected interval changes in left ventricular ejection fraction over 12 months

  • Heart Failure [ Time Frame: 12 months ]
    New onset of heart failure symptoms (NYHA II-IV)


Estimated Enrollment: 99
Actual Study Start Date: July 1, 2014
Estimated Study Completion Date: February 1, 2018
Estimated Primary Completion Date: February 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anakinra (standard dose)
Anakinra 100 mg daily for 14 days
Drug: Anakinra 100 mg
Anakinra 100 mg starting immediately and then every 24 hours
Other Name: Kineret
Drug: Placebo
Placebo 0.67 ml injections twice daily
Other Name: Placebo injections twice daily
Experimental: Anakinra (high dose)
Anakinra 100 mg twice daily for 14 days
Drug: Anakinra 100 mg
Anakinra 100 mg starting immediately and then every 24 hours
Other Name: Kineret
Drug: Anakinra 100 mg
Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
Other Name: Kineret
Placebo Comparator: Placebo
Placebo for 14 days
Drug: Placebo
Placebo 0.67 ml injections twice daily
Other Name: Placebo injections twice daily

Detailed Description:
VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and NONE of the Exclusion criteria.

  1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new
  2. Planned or completed coronary angiogram for potential intervention
  3. Age>21

EXCLUSION CRITERIA:

  • Inability to give informed consent
  • Pregnancy
  • Preexisting congestive heart failure (American Heart Association/American College of Cardiology class C-D, New York Heart Association III-IV)
  • Preexisting severe left ventricular dysfunction (EF<20%)
  • Preexisting severe valvular heart disease
  • Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with undetectable RNA
  • Recent (<14 days) or active use of anti-inflammatory drugs (not including non-steroidal anti-inflammatory drugs [NSAIDs] or corticosteroids used for IV dye allergy only)
  • Chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)
  • Active malignancy (or prior malignancy within the past 10 years) - excluding carcinoma in situ [any organ] and non-melanoma skin cancer
  • Anticipated need for cardiac surgery
  • Neutropenia (absolute neutrophil count<1,800/mm3)
  • Need for vaccination or desensitization that cannot be postponed for 14 days
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01950299


Contacts
Contact: Antonio Abbate, MD, PhD 804-828-0513 aabbate@vcu.edu
Contact: Benjamin W Van Tassell, PharmD 804-828-4583 bvantassell@vcu.edu

Locations
United States, District of Columbia
Washington Hospital Center Recruiting
Washington, D.C., District of Columbia, United States, 20010
Contact: Ron Waksman, MD    202-877-5975    Ron.Waksman@Medstar.net   
Contact: Michael J Lipinski, MD, PhD    202-877-5975      
United States, Virginia
Virginia Commonwealth University Recruiting
Richmond, Virginia, United States, 23298
Contact: Antonio Abbate, MD, PhD    804-828-0513    aabbate@vcu.edu   
Principal Investigator: Antonio Abbate, MD, PhD         
Sponsors and Collaborators
Virginia Commonwealth University
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Antonio Abbate, MD, PhD Virginia Commonwealth University
  More Information

Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT01950299     History of Changes
Other Study ID Numbers: HM20000024
1R34HL121402-01 ( U.S. NIH Grant/Contract )
First Submitted: September 4, 2013
First Posted: September 25, 2013
Last Update Posted: August 10, 2017
Last Verified: August 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Heart Diseases
Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents